What are the recent and forecasted trends in prescription drug spending?
This slideshow looks at past, present and future trends in prescription drug spending with a focus on the role of specialty drugs.
View the Latest: Prices
Filter
-
-
The 4 Arguments You Will Hear Against Drug Price Negotiation
PerspectiveAs the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF's Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
-
Understanding Mergers Between Hospitals and Health Systems in Different Markets
Issue BriefThis brief explains the role and implications of cross-market mergers between hospitals and health systems that operate in different regions and describes the approaches that government antitrust agencies have taken in reviewing these types of transactions.
-
Understanding the Role of the FTC, DOJ, and States in Challenging Anticompetitive Practices Of Hospitals and Other Health Care Providers
Issue BriefThis brief explains the role of federal and state antitrust agencies in challenging anticompetitive practices among hospitals and other health care providers, including the legal authority of federal and state agencies, the role that they play in enforcing antitrust laws, and proposed options for strengthening their authority.
-
Privately Insured People with Depression and Anxiety Face High Out-of-Pocket Costs
Issue BriefThis analysis finds that privately insured adults who were treated for depression and/or anxiety in 2021 spent almost twice as much on annual out-of-pocket costs compared to enrollees who were not treated for a mental health diagnosis.
-
After the COVID-19 Public Health Emergency Ends on May 11, Some Consumers Could Face High Prices for COVID-19 Testing
News ReleaseAfter the public health emergency ends on May 11, private health plans will no longer be required to cover the full cost of COVID-19 tests ordered or administered by a clinician or to reimburse consumers for at-home rapid tests.
-
Prices for COVID-19 Testing
Issue BriefThis analysis examines the potential costs for COVID-19 testing that some consumers may face once the COVID-19 public health emergency ends on May 11, 2023., depending on whether they have insurance and how their insurance covers testing.
-
How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?
Issue BriefThis analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.
-
Analysis: Inconsistencies Within Hospital Price Transparency Data Make Cost Comparisons Difficult
News ReleaseSince 2021, federal law has required hospitals to publicly post information about their standard prices and negotiated discount rates for common health services to encourage consumers to compare prices and to promote competition.
-
Ongoing Challenges with Hospital Price Transparency
Issue BriefThis analysis examines transparency data currently shared by hospitals to comply with federal law and finds that they are messy, inconsistent and confusing, making it challenging if not impossible for patients or researchers to use them to compare prices. Many of these shortcomings stem from a lack of specificity in the requirements for what hospitals must report.